Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Do investment tax breaks work? A new study finds the evidence is ‘mixed at best’ 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Apple Downgraded by Jefferies Amid Weak iPhone Sales and AI Concerns 
China's Refining Industry Faces Major Shakeup Amid Challenges 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Ferrari Group to Launch IPO in Amsterdam, Targets Over $1 Billion Valuation 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
U.S. Condemns China's Dominance in Global Shipbuilding and Maritime Sectors 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
How the UK’s rollback of banking regulations could risk another financial crisis 
SoftBank Eyes Up to $25B OpenAI Investment Amid AI Boom 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
